UNSPSC 51183113: Tolpyrramide

This classification denotes an anti-diabetic agent with the molecular formula C12H16N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W68DD2C7VG, chemically known as 1-pyrrolidinecarboxamide, n- (p-tolylsulfonyl)- but more generally known as tolpyrramide, which bears US NIH Compound Identifier 267368. European Medicines Agency schedules Tolpyrramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11177MIG.

UNSPSC 51183113 Tolpyrramide is a Commodity code for a specific pharmaceutical active ingredient, but state and local procurement activity under this code reflects the broader practice of acquiring generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles. The work involves supplying manufacturers' products at specified National Drug Codes (NDCs) and stockkeeping units to authorized wholesalers serving participating state and local government facilities, including hospitals, clinics, correctional facilities, and other health-service providers. Vendors must maintain current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, establish contractual relationships with designated wholesalers equipped with chargeback systems, and provide flexible pricing structures including flat-price, net-price, and WAC-minus formats. Required insurance includes $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. Products must meet FDA requirements, possess at least one-year expiration dates from manufacture, and be available in the marketplace by contract commencement.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities across Minnesota and Oregon, with a proposal due date of March 26, 2026. Award decisions are weighted primarily on price competitiveness (75 percent), with the remainder allocated to fixed pricing (10 percent), administrative fee compliance (5 percent), EDI capability (5 percent), and data format compliance (5 percent). Awarded vendors will pay a 3 percent administrative fee on all purchases and face performance penalties ranging from $200 to $1,500 per violation. The contract term is two years for new responders with optional extensions at MMCAP's discretion, and incumbent responders' amendments will align with existing agreement expiration dates through June 30, 2028. Specific award values are not disclosed, but the structure supports multi-award strategy based on therapeutic considerations, product availability, and member-specific needs.